MGF
Mechano-growth factor
MGF is an inconsistent term for an IGF-1 splice variant or a synthetic fragment derived from it; the two are not interchangeable.
Peptipedia explains research and prescribing information. It does not replace medical advice and is not an invitation to use a substance.
Identity not confirmed
The name may refer to different substance or product forms.
MGF can mean the full IGF-1Eb splice variant or a synthetic C-terminal fragment. Without sequence, modification, salt and analytical data, the catalogue substance is unresolved.
Research areas
Evidence matrix
- Molecular identity
- Partially clarified
MGF can mean the full IGF-1Eb splice variant or a synthetic C-terminal fragment. Without sequence, modification, salt and analytical data, the catalogue substance is unresolved.
- Human research
- None
- Replication
- Single research group
- Clinical endpoints
- No clinical endpoints
- Safety
- Not adequately studied
- Approval
- No documented approval
The dimensions are presented separately and are not combined into an overall score.
What the source shows
The cited replication study found no corresponding effects of the tested fragment in myoblasts or primary muscle stem cells.
- Mechano-growth factor peptide, the COOH terminus of unprocessed insulin-like growth factor 1, has no apparent effect on myoblasts or primary muscle stem cellsLaboratory study2014
Fornaro M et al.
Accessed:
Research gaps
- ·Findings for full-length IGF-1Eb do not validate the marketed fragment. Sequence, modification and salt must be resolved before assessment.
- ·Short profile: not a complete benefit–risk assessment. Unlisted contraindications and interactions are not adequately established in this profile; missing information does not establish safety.
Mechanism
Direct growth effects attributed to the separately considered C-terminal fragment are experimentally disputed.
- Mechano-growth factor peptide, the COOH terminus of unprocessed insulin-like growth factor 1, has no apparent effect on myoblasts or primary muscle stem cellsLaboratory study2014
Fornaro M et al.
Accessed:
Study protocols
No sufficiently supported, exactly citable study protocols are available.
Calculator
Arithmetic based only on your entries. Not a dose or use recommendation.
Reported adverse effects
- ·Evidence is insufficient; absence of data is not evidence of safety. Human exposure, pharmacokinetics and adequate toxicology are absent for the unresolved catalogue substance.
Contraindications and warnings
No reviewed information on this point has been recorded here yet. This does not mean there are no risks or contraindications.
Interactions
No reviewed information on this point has been recorded here yet. This does not mean there are no risks or contraindications.
Research gaps
- ·Findings for full-length IGF-1Eb do not validate the marketed fragment. Sequence, modification and salt must be resolved before assessment.
- ·Short profile: not a complete benefit–risk assessment. Unlisted contraindications and interactions are not adequately established in this profile; missing information does not establish safety.
- Mechano-growth factor peptide, the COOH terminus of unprocessed insulin-like growth factor 1, has no apparent effect on myoblasts or primary muscle stem cellsLaboratory study2014
Fornaro M et al.
Accessed:
Sources
Sources checked: · Version 3
- Mechano-growth factor peptide, the COOH terminus of unprocessed insulin-like growth factor 1, has no apparent effect on myoblasts or primary muscle stem cellsLaboratory study2014
Fornaro M et al.
Accessed: